Story of AminoChain: Platform Connecting Global Biosample & Research Data to Advance Pre-clinical Research
Story of AminoChain:
AminoChain is a biotechnology startup founded in 2022 by
Caspar Barnes, who serves as the company’s CEO. Barnes, with degrees in
Biotechnology and Finance, leads the company’s mission to revolutionize
biobanking and pre-clinical research through blockchain technology.
Company Mission
AminoChain aims to create a decentralized network connecting
global biosample and research data inventories. Its goal is to accelerate
pre-clinical research while ensuring patient ownership, privacy, and data
integrity.
Core Technology
The company leverages blockchain technology to build a
secure and transparent platform. AminoChain’s system allows biobanks and
research institutions to share biosamples and data while maintaining control
over their assets.
Key Team Members
Alongside Caspar Barnes, AminoChain is led by Co-Founder and
CTO Maximilian Mathews and Chief Business Development Officer Jelani Clarke,
PhD. Together, they guide the company’s technological innovation and strategic
growth.
Platform and Features
AminoChain’s main platform includes the “Specimen Center,” a
decentralized marketplace for biosamples. Patients and donors can track their
samples, access generated data, and earn revenue when samples are used for
research or commercial purposes.
Story of AminoChain: Platform Connecting Global Biosample & Research Data to Advance Pre-clinical Research#startup#net worth#investor#AminoChain story
Decentralized Biobank Concept
The platform prioritizes a patient-centric approach, giving
contributors ownership of their samples and intellectual property. Researchers
can query collections, request permissions, and license samples more
efficiently, streamlining pre-clinical research processes.
Funding and Investors
AminoChain has raised $7.57 million in seed funding from
investors including Andreessen Horowitz (a16z), Cercano Management, and Alumni
Ventures. This funding supports platform development, network expansion, and
commercialization of its biobanking solutions.
Applications and Integration
Medical institutions use AminoChain’s “Amino Node” software
to manage data securely while making it accessible for collaboration.
Developers can build user-owned healthcare applications on the platform,
expanding its utility beyond biosample exchange.
Impact on Research
By connecting biobanks, hospitals, and research institutions
globally, AminoChain increases transparency, accessibility, and efficiency in
pre-clinical research. Its blockchain infrastructure ensures accurate
record-keeping and trust across the network.
Future Vision
AminoChain plans to expand its decentralized biobank
infrastructure, tokenizing stem cell donations and enabling a more
collaborative biomedical ecosystem. The company’s mission is to transform
biobanking into a more patient-empowered, transparent, and efficient system
worldwide.
Timeline of AminoChain
- 2019-2021
– Caspar Barnes develops the concept of a decentralized biobank and
blockchain-based research platform.
- 2022
– AminoChain is officially founded in New York City.
- 2022-2023
– Seed funding of $7.57M secured from a16z, Cercano, and Alumni Ventures.
- 2023
onward – Launch of Specimen Center marketplace, deployment of Amino
Node software, and expansion of global biosample network.
